tradingkey.logo

Ginkgo Bioworks Holdings Inc

DNA

13.205USD

+1.015+8.33%
Market hours ETQuotes delayed by 15 min
722.29MMarket Cap
LossP/E TTM

Ginkgo Bioworks Holdings Inc

13.205

+1.015+8.33%
More Details of Ginkgo Bioworks Holdings Inc Company
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatic testing products and services primarily provided to public health authorities. It also focuses on the design of next-generation cell therapies for autoimmune diseases. It uses its platform to develop and screen libraries of novel NK-specific and T-cell specific chimeric antigen receptor and switch receptor designs, which enable control and performance of immune cell-based therapies.
Company Info
Ticker SymbolDNA
Company nameGinkgo Bioworks Holdings Inc
IPO dateApr 19, 2021
CEODr. Jason Kelly
Number of employees834
Security typeOrdinary Share
Fiscal year-endApr 19
Address27 Drydock Avenue
CityBOSTON
Stock exchangeNYSE Consolidated
CountryUnited States of America
Postal code02210
Phone18774425362
Websitehttps://investors.ginkgobioworks.com/
Ticker SymbolDNA
IPO dateApr 19, 2021
CEODr. Jason Kelly
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Harry Evans Sloan, J.D.
Mr. Harry Evans Sloan, J.D.
Independent Director
Independent Director
282.24K
+3.99%
Shyam Sankar
Shyam Sankar
Independent Chairman of the Board
Independent Chairman of the Board
83.19K
+14.95%
Mr. Christian O. Henry
Mr. Christian O. Henry
Independent Director
Independent Director
55.13K
+24.42%
Dr. Sri Kosuri
Dr. Sri Kosuri
Independent Director
Independent Director
48.13K
+100.00%
Dr. Kathy Hopinkah Hannan
Dr. Kathy Hopinkah Hannan
Independent Director
Independent Director
25.82K
+72.13%
Mr. Ross Fubini
Mr. Ross Fubini
Independent Director
Independent Director
21.64K
+100.00%
Steven P. Coen ,
Steven P. Coen ,
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Reshma Shetty
Dr. Reshma Shetty
President, Chief Operating Officer, Director
President, Chief Operating Officer, Director
--
--
Dr. Jason Kelly
Dr. Jason Kelly
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Harry Evans Sloan, J.D.
Mr. Harry Evans Sloan, J.D.
Independent Director
Independent Director
282.24K
+3.99%
Shyam Sankar
Shyam Sankar
Independent Chairman of the Board
Independent Chairman of the Board
83.19K
+14.95%
Mr. Christian O. Henry
Mr. Christian O. Henry
Independent Director
Independent Director
55.13K
+24.42%
Dr. Sri Kosuri
Dr. Sri Kosuri
Independent Director
Independent Director
48.13K
+100.00%
Dr. Kathy Hopinkah Hannan
Dr. Kathy Hopinkah Hannan
Independent Director
Independent Director
25.82K
+72.13%
Mr. Ross Fubini
Mr. Ross Fubini
Independent Director
Independent Director
21.64K
+100.00%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
United States
36.72M
76.00%
Undetermined
11.60M
24.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Jul 4
Updated: Fri, Jul 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Cascade Investment, L.L.C.
8.19%
Viking Global Investors LP
7.72%
Baillie Gifford & Co.
7.23%
The Vanguard Group, Inc.
5.14%
Anchorage Capital Group, L.L.C.
3.77%
Other
67.95%
Shareholders
Shareholders
Proportion
Cascade Investment, L.L.C.
8.19%
Viking Global Investors LP
7.72%
Baillie Gifford & Co.
7.23%
The Vanguard Group, Inc.
5.14%
Anchorage Capital Group, L.L.C.
3.77%
Other
67.95%
Shareholder Types
Shareholders
Proportion
Investment Advisor
27.30%
Investment Advisor/Hedge Fund
19.16%
Hedge Fund
15.44%
Family Office
8.19%
Individual Investor
6.87%
Research Firm
6.39%
Private Equity
1.32%
Pension Fund
0.27%
Venture Capital
0.23%
Other
14.82%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
658
35.81M
77.27%
-6.02M
2025Q1
685
36.18M
78.16%
-4.18M
2024Q4
706
35.80M
78.25%
+2.14M
2024Q3
730
30.06M
69.62%
+1.12M
2024Q2
734
26.68M
61.80%
-9.66M
2024Q1
721
34.68M
83.80%
-1.35M
2023Q4
701
34.15M
84.00%
-1.44M
2023Q3
691
33.72M
84.37%
-968.08K
2023Q2
739
33.27M
84.02%
-1.22M
2023Q1
698
31.86M
81.89%
+1.44M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Cascade Investment, L.L.C.
3.80M
8.19%
--
--
Apr 17, 2025
Viking Global Investors LP
3.58M
7.72%
--
--
Mar 31, 2025
Baillie Gifford & Co.
3.35M
7.23%
-6.50K
-0.19%
Mar 31, 2025
The Vanguard Group, Inc.
2.13M
4.59%
+117.45K
+5.85%
Mar 31, 2025
Anchorage Capital Group, L.L.C.
1.75M
3.77%
--
--
Mar 31, 2025
Erste Asset Management GmbH
1.65M
3.56%
+910.67K
+123.17%
Mar 31, 2025
Knight (Thomas F Jr)
1.48M
3.2%
-77.18K
-4.94%
Dec 31, 2023
EcoR1 Capital, LLC
1.46M
3.16%
-281.02K
-16.12%
Mar 31, 2025
Millennium Management LLC
1.43M
3.08%
+757.53K
+113.05%
Mar 31, 2025
Legal & General Investment Management Ltd.
1.42M
3.06%
+567.17K
+66.61%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
WisdomTree BioRevolution Fund
2.74%
ROBO Global Artificial Intelligence ETF
1.67%
iShares Genomics Immunology and Healthcare ETF
0.97%
US Vegan Climate ETF
0.12%
iShares Micro-Cap ETF
0.09%
AXS Green Alpha ETF
0.08%
Invesco RAFI US 1500 Small-Mid ETF
0.07%
iShares Biotechnology ETF
0.04%
Avantis US Small Cap Equity ETF
0.04%
SPDR S&P Kensho New Economies Composite ETF
0.03%
View more
WisdomTree BioRevolution Fund
Proportion2.74%
ROBO Global Artificial Intelligence ETF
Proportion1.67%
iShares Genomics Immunology and Healthcare ETF
Proportion0.97%
US Vegan Climate ETF
Proportion0.12%
iShares Micro-Cap ETF
Proportion0.09%
AXS Green Alpha ETF
Proportion0.08%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.07%
iShares Biotechnology ETF
Proportion0.04%
Avantis US Small Cap Equity ETF
Proportion0.04%
SPDR S&P Kensho New Economies Composite ETF
Proportion0.03%
Dividend
A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 05, 2024
Merger
40<1
Jul 05, 2024
Merger
40<1
Jul 05, 2024
Merger
40<1
Jul 05, 2024
Merger
40<1
Date
Type
Ratio
Jul 05, 2024
Merger
40<1
Jul 05, 2024
Merger
40<1
Jul 05, 2024
Merger
40<1
Jul 05, 2024
Merger
40<1
KeyAI